Ongoing clinical development study confirms Lifecare's expectation of a sensor
longevity that far exceeds the lifetime of existing and commercially available
needle sensors for glucose monitoring. 
 
Today Lifecare can report that sensors used in a three-day clinical study
continue to work in an in vitro set up, showing an operational longevity for a
total of 4 weeks and still ongoing. 
 
The current clinical trial sensor is not the final product, but it already
represents a major step forward for Lifecare's Sencell-technology. - We have 20
people in our outstanding team who have worked intensively to achieve these
results and everyone is thrilled to see the outcome, says CEO Joacim Holter. 
 
Lifecare is developing a Continuous Glucose Monitoring (CGM) sensor at the size
of a grain of rice, with an expected longevity exceeding those of existing
needle based CGM-systems. Lifecares sensor is currently subject to the
first-in-human studies. 
 
Longevity 
Lifecare CSO Prof. Andreas Pfützner describes the results as a breakthrough for
the product development of the sensor technology. - Now we have a first proof
that a sensor employing the miniaturized core Sencell technology has been
operational in the human body for several days continues to work in an in vitro
set-up for more than 4 weeks. This is not possible with a commercially available
needle sensor. The in vitro set-up experiment will continue, with the
expectation that we can confirm additional longevity in the months to follow.  
 
Beside the longevity, the study provides already strong indications that our
technology is at least as accurate and may be superior to commercially available
needle sensors. Our study is also an indication of the robustness of the sensing
technology - you can basically take the sensor in and out of the body and it
continues to measure correctly. 
 
- The study shows the stability and robustness of our technology, says Prof.
Pfützner, - and it is an indication that Lifecare is in the process of reaching
the planned long term of longevity. 
 
- As previously communicated, we have prolonged our technology development study
to clear out issues, improve the product, improve the performance of the
product, and improve the longevity of the product, summarizes Joacim Holter. 
 
The current status of the development study firmly confirms the groundbreaking
potential of the Sencell technology.  
 
This is Lifecare 
Lifecare is a Bergen-based technology company developing a miniaturized
implantable long-term sensor for correct and continuous monitoring of blood
sugar in people with diabetes. The Company's patented technology also has the
potential for use in various biomarkers. Lifecare AS is listed on Euronext
Growth (LIFE).

Further information
Joacim Holter, CEO, Lifecare AS,  joacim.holter@lifecare.no, +47 40 05 90 40

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Joacim Holter, CEO at Lifecare AS, on 6 February
2023 at 08:35 CET